These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 21256048)
21. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Simonneau G; Galiè N; Jansa P; Meyer GM; Al-Hiti H; Kusic-Pajic A; Lemarié JC; Hoeper MM; Rubin LJ Int J Cardiol; 2014 Mar; 172(2):332-9. PubMed ID: 24525158 [TBL] [Abstract][Full Text] [Related]
22. Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study. Frantz RP; Durst L; Burger CD; Oudiz RJ; Bourge RC; Franco V; Waxman AB; McDevitt S; Walker S J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):550-7. PubMed ID: 24742768 [TBL] [Abstract][Full Text] [Related]
23. Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension. Hsu HH; Chen JS; Chen RJ; Ko WJ; Kuo SW; Wu ET; Wu MH; Wang JK; Lee YC Respir Med; 2007 Jul; 101(7):1556-62. PubMed ID: 17223329 [TBL] [Abstract][Full Text] [Related]
24. Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life. Strange G; Keogh AM; Williams TJ; Wlodarczyk J; McNeil KD; Gabbay E Respirology; 2008 Sep; 13(5):674-82. PubMed ID: 18713089 [TBL] [Abstract][Full Text] [Related]
25. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Humbert M; Barst RJ; Robbins IM; Channick RN; Galiè N; Boonstra A; Rubin LJ; Horn EM; Manes A; Simonneau G Eur Respir J; 2004 Sep; 24(3):353-9. PubMed ID: 15358690 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension. Bharani A; Patel A; Saraf J; Jain A; Mehrotra S; Lunia B Indian Heart J; 2007; 59(4):323-8. PubMed ID: 19126937 [TBL] [Abstract][Full Text] [Related]
27. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355 [TBL] [Abstract][Full Text] [Related]
28. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664 [TBL] [Abstract][Full Text] [Related]
29. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn. Mohamed WA; Ismail M J Perinatol; 2012 Aug; 32(8):608-13. PubMed ID: 22076415 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease. Monfredi O; Griffiths L; Clarke B; Mahadevan VS Am J Cardiol; 2011 Nov; 108(10):1483-8. PubMed ID: 21943933 [TBL] [Abstract][Full Text] [Related]
33. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098 [TBL] [Abstract][Full Text] [Related]
34. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974 [TBL] [Abstract][Full Text] [Related]
35. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. Vizza CD; Jansa P; Teal S; Dombi T; Zhou D BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133 [TBL] [Abstract][Full Text] [Related]
36. Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension. Udeoji DU; Schwarz ER Ther Adv Respir Dis; 2013 Feb; 7(1):39-49. PubMed ID: 23129569 [TBL] [Abstract][Full Text] [Related]